Risk of long-term hot flashes after natural menopause: Evidence from the Penn Ovarian Aging Study cohort

Menopause

Volumn 21, Issue 9, 2014, Pages 924-932

  Freeman, Ellen W ^a   Sammel, Mary D ^a   Sanders, Richard J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Hormone therapy; Hot flashes; Menopause; Obesity; Race; Vasomotor symptoms

Indexed keywords

ESTRADIOL; FOLLITROPIN;

ADULT; AFRICAN AMERICAN; AGING; ANXIETY; ARTICLE; CAUCASIAN; COHORT ANALYSIS; DISEASE DURATION; EDUCATIONAL STATUS; EXPERIENCE; FEMALE; FOLLOW UP; HORMONAL THERAPY; HOT FLUSH; HUMAN; MENOPAUSAL SYNDROME; MENOPAUSE; POSTMENOPAUSE; PREMENOPAUSE; PREVALENCE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; ATTITUDE TO HEALTH; HOT FLASHES; LONGITUDINAL STUDY; PATHOLOGY; SEVERITY OF ILLNESS INDEX; UNITED STATES;

ADULT; AGING; ATTITUDE TO HEALTH; COHORT STUDIES; FEMALE; HOT FLASHES; HUMANS; LONGITUDINAL STUDIES; MENOPAUSE; PENNSYLVANIA; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84906940329     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000196     Document Type: Article

References (37)

1. National Institutes of Health, State-of-the-Science Panel. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med 2005;142:1003-1013.
2. Williams RE, Kalilani L, DiBenedetti DB, et al. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric 2008;11:32-43.
3. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310:1353-1368.
4. The North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257-271.
5. Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med 2008;23: 1507-1513.
6. Col NF, Guthrie JR, Politi M, Dennerstein L. Duration of vasomotor symptoms in middle-aged women: a longitudinal study. Menopause 2009; 16:453-457.
7. Blümel JE, Chedraui P, Baron G, et al. A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women. Menopause 2011;18:778-785.
8. Freeman EW, Sammel MD, Lin H, Liu Z, Gracia CR. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol 2011;117: 1095-1104.
9. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012;97:1159-1168.
10. Freeman EW, Sammel MD, Lin H, Gracia CR, Kapoor S, Ferdousi T. The role of anxiety and hormonal changes in menopausal hot flashes. Menopause 2005;12:258-266.
11. Freeman EW, Sammel MD, Liu L, Martin P. Psychometric properties of a menopausal symptom list. Menopause 2003;10:258-265.
12. Zung WWK. A rating instrument for anxiety disorders. Psychosomatics 1971;12:371-379.
13. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
14. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav 1983;24:385-396.
15. Ware J Jr, Kosinski M, Keller SD. A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-233.
16. Liang KY, Zeger SL. Longitudinal data analysis using generalized lineal models. Biometrika 1986;73:13-22.
17. Freeman EW, Sammel MD, Lin H, Boorman DW, Gracia CR. Contribution of the rate of change of antimüllerian hormone in estimating time to menopause for late reproductive-age women. Fertil Steril 2012;98: 1254-1259.
18. Avis NE, Crawford SL, Bromberger JT, Everson-Rose S, Greendale G, Gold EB. Duration of vasomotor symptoms during the menopausal transition [Abstract]. J Womens Health 2013;22:3.
19. Burger HG, Dudley EC, Hopper JL, et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population based cohort of women. J Clin Endocrinol Metab 1999;84:4025-4030.
20. Randolph JF Jr, Sowers M, Bondarenko IV, Harlow SD, Luborsky JL, Little RJ. Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age. J Clin Endocrinol Metab 2004;89:1555-1561.
21. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women's Health Across the Nation. Am J Public Health 2006;96:1226-1235.
22. Appling S, Paez K, Allen J. Ethnicity and vasomotor symptoms in postmenopausal women. J Womens Health 2007;16:1130-1138.
23. Simpkins JW, Brown K, Bae S, Ratka A. Role of ethnicity in the expression of features of hot flashes. Maturitas 2009;63:341-346.
24. Thurston RC, Bromberger JT, Joffe H, et al. Beyond frequency: who is most bothered by vasomotor symptoms? Menopause 2008;15:841-847.
25. Miller SR, Gallicchio LM, Lewis LM, et al. Association between race and hot flashes in midlife women. Maturitas 2006;54:260-269.
26. Freeman EW, Sammel MD, Lin H, Gracia CR. Obesity and reproductive hormone levels in the transition to menopause. Menopause 2010;17: 718-726.
27. Randolph JF Jr, Zheng H, Sowers MR, et al. Change in folliclestimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab 2011;96:746-754.
28. Bromberger JT, Kravitz HM, Chang Y, et al. Does risk for anxiety increase during the menopausal transition? Menopause 2013;20:488-495.
29. Woods NF, Mitchell ES, Landis C. Anxiety, hormonal changes, and vasomotor symptoms during the menopause transition. Menopause 2005; 12:242-245.
30. Lermer MA, Morra A, Moineddin R, Manson J, Blake J, Tierney MC. Somatic and affective anxiety symptoms and menopausal hot flashes. Menopause 2011;18:129-132.
31. Hanisch LJ, Hantsoo L, Freeman EW, Sullivan GM, Coyne JC. Hot flashes and panic attacks: a comparison of symptomatology, neurobiology, treatment, and a role for cognition. Psychol Bull 2008;134:247-269.
32. Freeman EW, Sammel MD, Grisso JA, Battistini M, Garica-Espagna B, Hollander L. Hot flashes in the late reproductive years: risk factors for African American and Caucasian women. J Womens Health 2001;10:67-76.
33. Sammel MD, Freeman EW, Liu Z, Lin H, Guo W. Factors that influence entry into stages of the menopausal transition. Menopause 2009;16: 1218-1227.
34. Butts SF, Freeman EW, Sammel MD, Queen K, Lin H, Rebbeck TR. Joint effects of smoking and gene variants involved in sex steroid metabolism on hot flashes in late reproductive-age women. J Clin Endocrinol Metab 2012;97:E1032-E1042.
35. Centers for Disease Control and Prevention (CDC). Smoking prevalence among women of reproductive age-United States, 2006. MMWR Morb Mortal Wkly Rep 2008;57:849-852.
36. Michnovicz JJ, Hershcopf RJ, Naganuma H, Bradlow HL, Fishman J. Increased 2 hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N Engl J Med 1986;315: 1305-1309.
37. Imai A, Matsumani K, Takagi H, Ichigo S. New generation nonhormonal management for hot flashes. Gynecol Endocrinol 2013;29:63-66.